PRAX: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Collaboration revenue	0	-
Program-specific expenses-Ulixacaltamide	53,542	-
Program-specific expenses-Vormatrigine	52,589	-
Program-specific expenses-Relutrigine	30,851	-
Program-specific expenses-Elsunersen	4,297	-
Program-specific expenses-Other Early State Assets	5,664	-
Personnel-related expenses	37,059	-
Stock-based compensation expense	24,003	-
Depreciation expense	112	-
Other segment expenses	21,037	-
Interest income	14,797	-
Net loss	-214,357	-140,423
Depreciation expense	112	93
Stock-based compensation expense	24,003	16,556
Non-cash operating lease expense	769	506
Amortization of premiums and discounts on marketable securities, net	2,921	2,216
Non-cash collaboration and license agreement expense	0	0
Prepaid expenses and other current assets	-5,534	-6,917
Accounts payable	18,291	16,304
Accrued expenses	-3,228	-4,806
Operating lease liabilities	-933	-614
Deferred revenue	0	0
Other	-13	-3
Net cash used in operating activities	-172,743	-107,686
Purchases of property and equipment	56	56
Purchases of marketable securities	233,537	158,404
Maturities of marketable securities	250,836	125,290
Net cash provided by (used in) investing activities	17,243	-33,170
Proceeds from stock offerings, net of issuance costs-Follow On Offering	0	0
Proceeds from stock offerings, net of issuance costs-License And Collaboration Agreement	0	0
Proceeds from stock offerings, net of issuance costs-At The Market Offering	89,263	83,263
Payments of tax withholdings related to vesting of restricted stock units	1,270	1,218
Proceeds from exercise of stock options and employee stock purchase plan purchases	1,662	854
Net cash provided by financing activities	89,655	82,899
(decrease) increase in cash, cash equivalents and restricted cash	-65,845	-57,957
Cash and cash equivalents at beginning of period	215,788	-
Cash and cash equivalents at end of period	149,943	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

PRAX: the cashflow